Komen’s Position on Stem Cells Remains Unclear

Ticker

Monika Bauerlein,
CEO

Dear Reader,

The next few months are make-or-break for Mother Jones’ fundraising, and we need more online readers to pitch in than have been of late. In "It's Not a Crisis. This Is the New Normal," we take a level-headed look at the brutal economics of journalism, why investigative reporting like you get from us matters, and why we're optimistic we can grow our base of support in a big way—starting with hitting a huge $300,000 goal in just three weeks. Please learn more and donate if you can right now.

The next few months are make-or-break for Mother Jones’ fundraising. We need to raise $300,000 quickly, and we need more online readers to pitch in than have been. Please learn more in "It's Not a Crisis. This Is the New Normal," where we go into the brutal economics of journalism, and what makes Mother Jones unique and worth supporting if you can right now.

<a href="http://www.flickr.com/photos/inthehandofdante/3929434629/sizes/z/in/photostream/">timbrauhn</a>/Flickr

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Susan G. Komen for the Cure has hedged its decision to stop providing grants to Planned Parenthood for breast cancer screenings after that move kicked off a good deal of outrage. But it’s still not clear where the group stands on embryonic stem cell research, another subject that has made Komen a target of anti-abortion groups.

Anti-abortion groups have been pressuring Komen to stop providing millions in support to research institutions like Johns Hopkins University School of Medicine and the U.S. National Cancer Institute because those organizations also conduct research using embryonic stem cells.

As we reported yesterday, news outlets affiliated with the anti-abortion rights movement have been touting a recent press release from Komen that insists that it is not funding embryonic stem cell research and does not support any cancer research that involves “destroying a human embryo.”

A reader managed to find a copy of the Nov. 30 press release, which has since disappeared from Komen’s website. I’ve posted that document here, and it definitely seems to suggest that Komen now opposes embryonic stem cell research. That wasn’t the case a few years ago, when this Komen newsletter touted the potential benefits of using embryonic stem cells:

Embryonic stem cells (derived from embryos that develop from eggs that have been fertilized in vitro and then donated for research purposes) have the potential to give rise to many different types of tissue. Because of this, embryonic stem cells are currently considered to have the most potential for use in the regeneration of diseased or injured tissues. Another potential role is providing a better understanding of cancer development.

The National Cancer Institute notes that “embryonic stem cells hold far more potential than adult cells” when it comes to research, because embryonic cells “can change into more tissue types and replicate indefinitely, two properties not generally shown with adult cells.”

I’ve asked Komen to comment on whether they have formally changed their position on this type of research, but have not received a response. Although many are heralding Komen’s semi-cave on Planned Parenthood, the group’s current position is on stem cell research is still a mystery, and one that needs to be resolved—particularly since research on “a cure” is central to Komen’s mission.